<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209131</url>
  </required_header>
  <id_info>
    <org_study_id>0128-2005</org_study_id>
    <nct_id>NCT00209131</nct_id>
  </id_info>
  <brief_title>Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy</brief_title>
  <official_title>Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of kidney stones are treated with shock wave lithotripsy (SWL). We are examining
      if the medication Flomax will result in improved stone passage rates following SWL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Placebo blinded study examining the effects of Flomax on stone passage rates following SWL.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to frequent turnover of research coordinators and thus poor study accrual.
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Passage of Stone Fragments</measure>
    <time_frame>2 weeks and 3 months</time_frame>
    <description>Time to passage of stone fragments following shock wave lithotripsy as documented by patient diaries and follow-up radiographic imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medical Evaluation</measure>
    <time_frame>2 weeks and 3 months</time_frame>
    <description>Evaluation of pain assessments, lower urinary tract symptoms, side effects of study medication and need for hospitalizations and additional endoscopic procedures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>Flomax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flomax</intervention_name>
    <description>0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.</description>
    <arm_group_label>Flomax</arm_group_label>
    <other_name>Tamsulosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Placebo pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years old and above with urolithiasis scheduled for shock wave
             lithotripsy.

        Exclusion Criteria:

          -  Contraindications to Flomax

          -  Patients with renal impairment (serum creatinine above 2.0)

          -  Patients with hepatic impairment (liver enzymes 2.5 times the upper limit of normal)

          -  Use of other oral alpha blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Ogan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>June 5, 2012</results_first_submitted>
  <results_first_submitted_qc>June 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2012</results_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Kenneth Ogan, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>urolithiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment took place in a medical clinic affiliated with a teaching hospital from May 2005 through February 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Flomax</title>
          <description>Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">Patients enrolled for participation but did not complete the study.</participants>
                <participants group_id="P2" count="11">Patients enrolled for participation but did not complete the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Lack of personnel for adequate followup and data collection.</participants>
                <participants group_id="P2" count="0">Lack of personnel for adequate followup and data collection.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of personnel due to turnovers.</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flomax</title>
          <description>Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="5"/>
                    <measurement group_id="B2" value="53" spread="5"/>
                    <measurement group_id="B3" value="54" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Passage of Stone Fragments</title>
        <description>Time to passage of stone fragments following shock wave lithotripsy as documented by patient diaries and follow-up radiographic imaging.</description>
        <time_frame>2 weeks and 3 months</time_frame>
        <population>No analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Flomax</title>
            <description>Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Passage of Stone Fragments</title>
          <description>Time to passage of stone fragments following shock wave lithotripsy as documented by patient diaries and follow-up radiographic imaging.</description>
          <population>No analysis was conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No analysis was conducted.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Other</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Evaluation</title>
        <description>Evaluation of pain assessments, lower urinary tract symptoms, side effects of study medication and need for hospitalizations and additional endoscopic procedures.</description>
        <time_frame>2 weeks and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flomax</title>
            <description>Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Evaluation</title>
          <description>Evaluation of pain assessments, lower urinary tract symptoms, side effects of study medication and need for hospitalizations and additional endoscopic procedures.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Flomax</title>
          <description>Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated due to turnovers of personnel to assist with recruitment and execution of the study.Recruitment was strained and patients recruited could not be followed up in a timely fashion to adhere to protocol. Thus, no data was generated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kenneth Ogan</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-4898</phone>
      <email>kogan@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

